Helix BioPharma Corp. Announces Appointment of New Director

RICHMOND HILL, ONTARIO – Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno- oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that Dr. Krzysztof Saczek has been appointed as a member of the Board of Directors of the Company effective immediately.